5-Phenoxytryptamine

5-Phenoxytryptamine, also known as OVT2 or Otava 3736689, is a psychedelic drug of the tryptamine family related to 5-methoxytryptamine. It is the derivative of tryptamine and 5-methoxytryptamine in which there is a phenoxy group at the 5 position. The drug acts as a biased agonist of the serotonin 5-HT_2A receptor, favoring G_αi signaling over G_αq and β-arrestin1 signaling, though not favoring G_αq signaling over β-arrestin2 signaling. Its affinity for the serotonin 5-HT_2A receptor is 57.5nM and its activational potency at this receptor ranges from 0.28nM to 15,800nM and efficacy ranges from 30% to 91% depending on the downstream signaling pathway. OTV2, given via intracerebroventricular injection, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In addition, it produces long-term memory deficits that are dependent on serotonin 5-HT_2A receptor activation in rodents. The drug was first described in the scientific literature by Elk Kossatz and colleagues in 2024.